1. Home
  2. MTSR vs SKT Comparison

MTSR vs SKT Comparison

Compare MTSR & SKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTSR
  • SKT
  • Stock Information
  • Founded
  • MTSR 2022
  • SKT 1981
  • Country
  • MTSR United States
  • SKT United States
  • Employees
  • MTSR N/A
  • SKT N/A
  • Industry
  • MTSR
  • SKT Real Estate Investment Trusts
  • Sector
  • MTSR
  • SKT Real Estate
  • Exchange
  • MTSR NYSE
  • SKT Nasdaq
  • Market Cap
  • MTSR 3.0B
  • SKT 3.3B
  • IPO Year
  • MTSR 2025
  • SKT 1993
  • Fundamental
  • Price
  • MTSR $29.60
  • SKT $30.03
  • Analyst Decision
  • MTSR Strong Buy
  • SKT Buy
  • Analyst Count
  • MTSR 6
  • SKT 8
  • Target Price
  • MTSR $55.25
  • SKT $37.00
  • AVG Volume (30 Days)
  • MTSR 1.0M
  • SKT 961.0K
  • Earning Date
  • MTSR 05-12-2025
  • SKT 08-04-2025
  • Dividend Yield
  • MTSR N/A
  • SKT 3.88%
  • EPS Growth
  • MTSR N/A
  • SKT N/A
  • EPS
  • MTSR N/A
  • SKT 0.85
  • Revenue
  • MTSR N/A
  • SKT $549,227,000.00
  • Revenue This Year
  • MTSR N/A
  • SKT $0.92
  • Revenue Next Year
  • MTSR N/A
  • SKT $4.18
  • P/E Ratio
  • MTSR N/A
  • SKT $35.53
  • Revenue Growth
  • MTSR N/A
  • SKT 12.63
  • 52 Week Low
  • MTSR $12.30
  • SKT $25.94
  • 52 Week High
  • MTSR $37.99
  • SKT $37.57
  • Technical
  • Relative Strength Index (RSI)
  • MTSR N/A
  • SKT 49.04
  • Support Level
  • MTSR N/A
  • SKT $29.62
  • Resistance Level
  • MTSR N/A
  • SKT $30.25
  • Average True Range (ATR)
  • MTSR 0.00
  • SKT 0.60
  • MACD
  • MTSR 0.00
  • SKT 0.06
  • Stochastic Oscillator
  • MTSR 0.00
  • SKT 58.01

About MTSR METSERA INC

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

About SKT Tanger Inc.

Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.

Share on Social Networks: